Suppr超能文献

相似文献

1
Phage cocktail powder for Pseudomonas aeruginosa respiratory infections.
Int J Pharm. 2021 Mar 1;596:120200. doi: 10.1016/j.ijpharm.2021.120200. Epub 2021 Jan 21.
2
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Eur J Pharm Biopharm. 2019 Sep;142:543-552. doi: 10.1016/j.ejpb.2019.08.004. Epub 2019 Aug 6.
3
Storage stability of phage-ciprofloxacin combination powders against Pseudomonas aeruginosa respiratory infections.
Int J Pharm. 2020 Dec 15;591:119952. doi: 10.1016/j.ijpharm.2020.119952. Epub 2020 Oct 12.
4
Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.
Eur J Pharm Biopharm. 2017 Dec;121:1-13. doi: 10.1016/j.ejpb.2017.09.002. Epub 2017 Sep 7.
5
Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01714-17. Print 2018 Feb.
6
Inhaled Delivery of Anti-Pseudomonal Phages to Tackle Respiratory Infections Caused by Superbugs.
J Aerosol Med Pulm Drug Deliv. 2022 Apr;35(2):73-82. doi: 10.1089/jamp.2021.0045. Epub 2021 Dec 30.
7
Storage stability of inhalable phage powders containing lactose at ambient conditions.
Int J Pharm. 2019 Apr 5;560:11-18. doi: 10.1016/j.ijpharm.2019.01.050. Epub 2019 Jan 31.
8
Effect of storage temperature on the stability of spray dried bacteriophage powders.
Eur J Pharm Biopharm. 2018 Jun;127:213-222. doi: 10.1016/j.ejpb.2018.02.033. Epub 2018 Feb 24.
9
Feasibility of spray drying bacteriophages into respirable powders to combat pulmonary bacterial infections.
Eur J Pharm Biopharm. 2013 Aug;84(3):578-82. doi: 10.1016/j.ejpb.2012.12.022. Epub 2013 Jan 23.

引用本文的文献

1
Latest Advances in Inhalable Dry Powder Bacteriophage Therapy for Pulmonary Infections.
Pharmaceutics. 2025 Aug 20;17(8):1077. doi: 10.3390/pharmaceutics17081077.
2
Design of respirable sprayed microparticles of encapsulated bacteriophages.
Front Drug Deliv. 2023 Jun 14;3:1209534. doi: 10.3389/fddev.2023.1209534. eCollection 2023.
3
Long-term Storage Stability of Inhalable Phage Powder Formulations: A Four-Year Study.
AAPS J. 2025 Aug 4;27(5):128. doi: 10.1208/s12248-025-01112-y.
5
Deciphering Multidrug-Resistant : Mechanistic Insights and Environmental Risks.
Toxics. 2025 Apr 12;13(4):303. doi: 10.3390/toxics13040303.
6
Formulation of Bacteriophage for Inhalation to Treat Multidrug-Resistant Pulmonary Infections.
Kona. 2025;42:200-212. doi: 10.14356/kona.2025016. Epub 2024 Aug 14.
7
Bridging the gap: Phage manufacturing processes from laboratory to agri-food industry.
Virus Res. 2025 Mar;353:199537. doi: 10.1016/j.virusres.2025.199537. Epub 2025 Jan 31.
9
The Potential of Phage Treatment to Inactivate Planktonic and Biofilm-Forming .
Microorganisms. 2024 Aug 29;12(9):1795. doi: 10.3390/microorganisms12091795.
10
Phage therapy: breathing new tactics into lower respiratory tract infection treatments.
Eur Respir Rev. 2024 Jun 26;33(172). doi: 10.1183/16000617.0029-2024. Print 2024 Apr.

本文引用的文献

1
In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation.
Adv Drug Deliv Rev. 2020 Dec;167:135-147. doi: 10.1016/j.addr.2020.06.023. Epub 2020 Jun 25.
2
Does upper airway deformation affect drug deposition?
Int J Pharm. 2019 Dec 15;572:118773. doi: 10.1016/j.ijpharm.2019.118773. Epub 2019 Oct 31.
3
Inhalable combination powder formulations of phage and ciprofloxacin for P. aeruginosa respiratory infections.
Eur J Pharm Biopharm. 2019 Sep;142:543-552. doi: 10.1016/j.ejpb.2019.08.004. Epub 2019 Aug 6.
4
Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus.
Nat Med. 2019 May;25(5):730-733. doi: 10.1038/s41591-019-0437-z. Epub 2019 May 8.
6
Storage stability of inhalable phage powders containing lactose at ambient conditions.
Int J Pharm. 2019 Apr 5;560:11-18. doi: 10.1016/j.ijpharm.2019.01.050. Epub 2019 Jan 31.
7
Jet nebulization of bacteriophages with different tail morphologies - Structural effects.
Int J Pharm. 2019 Jan 10;554:322-326. doi: 10.1016/j.ijpharm.2018.11.026. Epub 2018 Nov 13.
8
Targeting mechanisms of tailed bacteriophages.
Nat Rev Microbiol. 2018 Dec;16(12):760-773. doi: 10.1038/s41579-018-0070-8.
9
Proof-of-Principle Study in a Murine Lung Infection Model of Antipseudomonal Activity of Phage PEV20 in a Dry-Powder Formulation.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01714-17. Print 2018 Feb.
10
Production of highly stable spray dried phage formulations for treatment of Pseudomonas aeruginosa lung infection.
Eur J Pharm Biopharm. 2017 Dec;121:1-13. doi: 10.1016/j.ejpb.2017.09.002. Epub 2017 Sep 7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验